Literature DB >> 3646103

Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects.

C A Youngberg, R R Berardi, W F Howatt, M L Hyneck, G L Amidon, J H Meyer, J B Dressman.   

Abstract

The primary objective of this study was to define the pH conditions under which supplemental pancreatic enzyme preparations must function in the upper gastrointestinal tract. The hypothesis was that normal or greater acid output in patients with cystic fibrosis (CF), combined with low pancreatic bicarbonate output, results in an acidic duodenal pH, compromising both dosage-form performance and enzyme activity. Gastrointestinal pH profiles were obtained in 10 CF and 10 healthy volunteers under fasting and postprandial conditions. A radiotelemetric monitoring method, the Heidelberg capsule, was used to continuously monitor pH. Postprandial duodenal pH was lower in CF than in healthy subjects, especially in the first postprandial hour (mean time greater than pH 6 was 5 min in CF, 11 min in healthy subjects, P less than 0.05). Based on the dissolution pH profiles of current enteric-coated pancreatic enzyme products, the duodenal postprandial pH in CF subjects may be too acidic to permit rapid dissolution of current enteric-coated dosage forms. However, the pH was above 4 more than 90% of the time on the average, suggesting that irreversible lipase inactivation in the duodenum is not likely to be a significant limitation to enzyme efficacy. Overall results suggest that slow dissolution of pH-sensitive coatings, rather than enzyme inactivation, may contribute to the failure of enteric-coated enzyme supplements to normalize fat absorption.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3646103     DOI: 10.1007/BF01296029

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  39 in total

1.  Influence of exocrine pancreatic insufficiency on the intraluminal pH of the proximal small intestine.

Authors:  S K Dutta; R M Russell; F L Iber
Journal:  Dig Dis Sci       Date:  1979-07       Impact factor: 3.199

2.  Duodenal fluid pH in cystic fibrosis.

Authors:  R E Knauff; J A Adams
Journal:  Clin Chem       Date:  1968-05       Impact factor: 8.327

3.  Heidelberg capsule. I. In vitro evaluation of a new instrument for measuring intragastric pH.

Authors:  W H Steinberg; F A Mina; P G Pick; G H Frey
Journal:  J Pharm Sci       Date:  1965-05       Impact factor: 3.534

4.  Studies on intestinal pH by radiotelemetering.

Authors:  W C Watson; E Paton
Journal:  Gut       Date:  1965-12       Impact factor: 23.059

5.  Comparative study of varying regimens to improve steatorrhoea and creatorrhoea in cystic fibrosis: Effectiveness of an enteric-coated preparation with and without antacids and cimetidine.

Authors:  R Gow; R Bradbear; P Francis; R Shepherd
Journal:  Lancet       Date:  1981-11-14       Impact factor: 79.321

6.  Intraduodenal events in cystic fibrosis.

Authors:  A M Weber; C C Roy
Journal:  J Pediatr Gastroenterol Nutr       Date:  1984       Impact factor: 2.839

7.  Effectiveness of cimetidine as an adjunct to supplemental pancreatic enzymes in patients with cystic fibrosis.

Authors:  V S Hubbard; G D Dunn; L A Lester
Journal:  Am J Clin Nutr       Date:  1980-11       Impact factor: 7.045

Review 8.  Cystic fibrosis and malnutrition.

Authors:  H P Chase; M A Long; M H Lavin
Journal:  J Pediatr       Date:  1979-09       Impact factor: 4.406

9.  Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis.

Authors:  P R Durie; L Bell; W Linton; M L Corey; G G Forstner
Journal:  Gut       Date:  1980-09       Impact factor: 23.059

10.  Diagnostic and therapeutic applications of bentiromide screening test for exocrine pancreatic insufficiency in patients with cystic fibrosis. Comparison with other tests of exocrine pancreatic disease.

Authors:  V S Hubbard; R O Wolf; L A Lester; A C Egge
Journal:  Dig Dis Sci       Date:  1984-10       Impact factor: 3.199

View more
  26 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  The use of biorelevant dissolution media to forecast the in vivo performance of a drug.

Authors:  Sandra Klein
Journal:  AAPS J       Date:  2010-05-11       Impact factor: 4.009

3.  Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule.

Authors:  Daniel Gelfond; Changxing Ma; Jack Semler; Drucy Borowitz
Journal:  Dig Dis Sci       Date:  2012-05-17       Impact factor: 3.199

Review 4.  Small-intestinal abnormalities in cystic fibrosis patients.

Authors:  E Eggermont; K De Boeck
Journal:  Eur J Pediatr       Date:  1991-10       Impact factor: 3.183

Review 5.  Pharmacokinetics of drugs in cystic fibrosis.

Authors:  M Spino
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 6.  Uses and abuses of enzyme therapy in cystic fibrosis.

Authors:  P Durie; D Kalnins; L Ellis
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

Review 7.  A Quantitative Review and Meta-Models of the Variability and Factors Affecting Oral Drug Absorption-Part I: Gastrointestinal pH.

Authors:  Ahmad Y Abuhelwa; David J R Foster; Richard N Upton
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

Review 8.  A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption-Part II: Gastrointestinal Transit Time.

Authors:  Ahmad Y Abuhelwa; David J R Foster; Richard N Upton
Journal:  AAPS J       Date:  2016-07-20       Impact factor: 4.009

9.  Kinetics of release from enteric-coated tablets.

Authors:  S S Ozturk; B O Palsson; B Donohoe; J B Dressman
Journal:  Pharm Res       Date:  1988-09       Impact factor: 4.200

10.  Upper gastrointestinal (GI) pH in young, healthy men and women.

Authors:  J B Dressman; R R Berardi; L C Dermentzoglou; T L Russell; S P Schmaltz; J L Barnett; K M Jarvenpaa
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.